Advertisement

Jean-Charles Soria, MD, PhD, Receives 2018 ESMO Award


Advertisement
Get Permission

Jean-Charles Soria, MD, PhD

Jean-Charles Soria, MD, PhD

The European Society for medical oncology (ESMO) has granted the 2018 ESMO Award to Jean-Charles Soria, MD, PhD, an international lung cancer expert and pioneer in the development of anticancer drugs. The award was founded in 1985 to acknowledge an ESMO member who has made contributions to the development of medical oncology as a specialty within the oncology community.

Dr. Soria’s research has been focused mainly on early clinical development, pharmacodynamic biomarkers, lung cancer management, and personalized medicine. He has been involved in translational research related to precision medicine and tumor progression, notably in lung cancer models, and has led multiple precision medicine trials. 

[Dr.] Soria has been a true leader to the medical oncology community. He has been an inspiration for the young generation with his great lectures….
— Evandro de Azambuja, MD, PhD

Tweet this quote

ESMO Fellowship and Award Committee Chair Evandro de Azambuja, MD, PhD, commented: “[Dr.] Soria has been a true leader to the medical oncology community. He has been an inspiration for the young generation with his great lectures and as Editor-in-Chief of Annals of Oncology ensured that ESMO’s journal was ‘among the best oncology journals.’” Dr. Soria was Editor-in-Chief of Annals of Oncology from 2014 to 2017.

“I want to mention with deep emotion my mentor Professor Thomas Tursz, recipient of the ESMO Award for Translational Research in 1998, who died suddenly this year and contributed greatly to who I am as a professional,” stated Dr. Soria.

Dr. Soria has been Professor of Medicine and Medical Oncology, University of Paris-Sud since 2006. From 2013 to 2017, he was Head of the Drug Development Department, Gustave Roussy, Villejuif, France, and Adjunct Professor, The University of Texas MD Anderson Cancer Center, Houston. He is currently Senior Vice President and Head of the Oncology Innovative Medicines Unit at MedImmune. ■


Advertisement

Advertisement



Advertisement